

High intensity community-based opioid treatment teams

In 2024, the Washington State Legislature, as noted in Sec. 215 (136) of Engrossed Substitute Senate Bill 5950, appropriated funds to establish high-intensity community-based teams serving people with opioid use disorder.

Overview

Funding will be used to significantly increase administration of long-acting injectable buprenorphine to people at highest risk for overdose.

The high-intensity community-based teams must be able to enhance low-barrier services to engage individuals with opioid use disorder and increase access to those most at risk of opioid overdose. Low barrier access must be available in areas with high rates of overdose in nontraditional settings such as supportive housing, shelters, and encampments where access to traditional care is difficult to access.

These teams must also engage people with opioid use disorder to provide low-barrier, immediate, and continual care to initiate Medication for Opioid Use Disorder (MOUD) with preferential focus on long-acting injectable buprenorphine.

Eligibility requirements

This funding opportunity is open to:

- Existing field-based programs funded with federal state opioid response grants and their subcontractors
- Low-barrier buprenorphine programs
- Street medicine teams

Budget for SFY 25 and SFY 26

HCA has been appropriated one time funding not to exceed \$3,000,000:

- \$1,500,000 for state fiscal year (SFY) 2025
- \$1,500,000 for SFY 2026

Partners

Partners will be determined through a competitive procurement process. Timeline for solicitation is as follows and you can [learn more by reading the FAQ](#):

- September 16, 2024: GovDelivery and Survey of Interest opens
- October 2, 2024: Listening session and Q&A
- October 25, 2024: Survey of Interest closes
- November 2024: Award contracts

For more information

Contact: HCADBHRInformation@hca.wa.gov

Cayla Rauh, Overdose Response Medication
Program Director